SCHEMBL4603002

SCHEMBL4603002

CC(C)(C)OC(=O)NCCCc1cccnc1

nearest known ligand 0.69

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.69
EPHX2 P34913 1/20 0.52
NAMPT P43490 1/20 0.52
PTAFR P25105 3/20 0.50
CHRNA7 P36544 1/20 0.49
TBXAS1 P24557 4/20 0.49
FES P07332 1/20 0.49
RET P07949 1/20 0.49
MARK3 P27448 1/20 0.49
TYK2 P29597 1/20 0.49
FLT4 P35916 1/20 0.49
SYK P43405 1/20 0.49
CLK2 P49760 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
SIGMAR1 Q99720 1/20 0.48
ALDH1A1 P00352 1/20 0.48
FAAH O00519 1/20 0.48
FKBP1A P62942 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29357760 1.00 CYP3A4 (0.69) CYP3A4EPHX2NAMPTPTAFRCHRNA7
SCHEMBL27507343 0.96 CYP3A4 (0.71) CYP3A4NAMPTPTAFRTBXAS1FES
SCHEMBL23291173 0.85 CYP3A4 (0.56) CYP3A4NAMPTCHRNA7FAAH
SCHEMBL479925 0.83 CYP3A4 (0.72) CYP3A4NAMPTFESRETMARK3
SCHEMBL8129760 0.83 CYP3A4 (0.52) CYP3A4SIGMAR1
SCHEMBL21591485 0.83 CYP3A4 (0.52) CYP3A4SIGMAR1
SCHEMBL4583683 0.83 POLB (0.65) EPHX2SIGMAR1
SCHEMBL20715219 0.82 CYP3A4 (1.00) CYP3A4NAMPTFESRETMARK3
SCHEMBL23928824 0.82 CYP3A4 (0.60) CYP3A4NAMPTPTAFRALDH1A1FAAH
SCHEMBL17196024 0.82 CYP3A4 (0.48) CYP3A4SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018091598-A2 TREATMENT OF NEURODEGENERATIVE DISEASES ICM (INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE) (FR) 2018-05-24 WO disclosed
EP-3323415-A1 TREATMENT OF NEURODEGENERATIVE DISEASES Institut du Cerveau et de la Moelle Epiniere-ICM (FR) 2018-05-23 EP disclosed
EP-1915363-A1 OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS AstraZeneca AB (SE) 2008-04-30 EP disclosed
WO-2007018469-A1 OXOPYRIDYL QUINOLINE AMIDES AS NK3 RECEPTOR MODULATORS ASTRAZENECA AB (SE) 2007-02-15 WO disclosed